Department of Nephrology, National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, 210016, China.
Int Urol Nephrol. 2020 Apr;52(4):731-738. doi: 10.1007/s11255-020-02415-z. Epub 2020 Mar 2.
We evaluated the clinical manifestations and outcomes of nocardiosis, a rare opportunistic infection that occurs in patients with nephrotic syndrome.
The records of NS patients with nocardiosis in a single hospital during 2000-2019 were retrieved and studied in detail.
Eleven patients were included. The mean time to develop nocardiosis after glucocorticoid therapy was 11.5 ± 14.8 months. Most patients had fever, elevated white blood cell counts and C-reactive protein, whereas procalcitonin levels were normal or slightly elevated in 91% (10/11) patients, except one patient suffered from septic shock. Nine patients were tested for CD4 T-cell counts; of these, four patients had counts < 200 cells/μL. The most common site of nocardiosis involvement was lung (100%), followed by subcutaneous tissue (72.7%). Radiological findings for lungs in seven cases were characterized by isolated or scattered nodules and masses, usually located subpleural or close to the hilum. Positive smears of Nocardia were detected in 100% of samples of subcutaneous abscess and pleural fluid. Nine patients received oral trimethoprim-sulfamethoxazole, four of which received combined carbapenem, and the remaining two patients received carbapenem monotherapy. The long-term prognosis was excellent, with a treatment success rate of 100% in all patients.
NS patients can develop immunodeficiency after treatment with glucocorticoid and immunosuppressants. In cases where patients develop systemic multiple abscesses, or lung images reveal isolated or scattered nodules and masses that are subpleural or close to the hilum, nocardial infection should be considered. Early diagnosis and specific treatment may improve patient outcomes.
我们评估了诺卡氏菌病的临床表现和结局,诺卡氏菌病是一种罕见的机会性感染,发生在肾病综合征患者中。
我们详细检索了 2000 年至 2019 年期间在一家医院就诊的患有诺卡氏菌病的肾病综合征患者的病历。
共纳入 11 例患者。应用糖皮质激素治疗后发生诺卡氏菌病的平均时间为 11.5±14.8 个月。大多数患者有发热、白细胞计数和 C 反应蛋白升高,而除了一例患者发生感染性休克外,91%(10/11)的患者降钙素原水平正常或轻度升高。9 例患者检测了 CD4 T 细胞计数,其中 4 例患者的计数<200 个/μL。诺卡氏菌病最常见的受累部位是肺部(100%),其次是皮下组织(72.7%)。7 例肺部病变的影像学表现为孤立或散在的结节和肿块,通常位于胸膜下或靠近肺门。皮下脓肿和胸腔积液标本中均 100%检测到诺卡氏菌的阳性涂片。9 例患者接受了口服复方磺胺甲噁唑治疗,其中 4 例联合了碳青霉烯类抗生素,其余 2 例仅接受了碳青霉烯类抗生素单药治疗。所有患者的治疗成功率均为 100%,长期预后良好。
肾病综合征患者在接受糖皮质激素和免疫抑制剂治疗后可能会发生免疫缺陷。当患者出现全身多发脓肿,或肺部影像学表现为孤立或散在的结节和肿块,且位于胸膜下或靠近肺门时,应考虑诺卡氏菌感染。早期诊断和特异性治疗可能改善患者的结局。